Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate explained
Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women.[1] It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection. The medication was developed by 1957. It is no longer available.[2] [3]
See also
- List of combined sex-hormonal preparations § Estrogens, progestogens, and androgens
Notes and References
- Ermiglia G, Valli P . Studio sul triormon depositum nella sindrome climaterica; curve di eliminazione dei cataboliti e durata dell'effetto terapeutico . Study of tribormone depositum in the climacteric syndrome; catabolite elimination curves and duration of the therapeutic effect . it . Quaderni di Clinica Ostetrica e Ginecologica . May 1957 . 12 . 5 . 284–93 . 0033-491X . 13465973 . Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory..
- Web site: Home . micromedexsolutions.com.
- https://www.drugs.com/international/triormon.html
